flow trial semaglutide kidney outcomes In FLOW, semaglutide, a GLP-1 RA, reduced the risk of major outcomes, MACE and all-cause mortality in people with T2D and CKD, regardless of baseline mineralocorticoid receptor antagonist use. @ADA_Pubs Read Media Centre | EASD
Pay in 4 interest-free payments of $5.66 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12













:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)










